体外培养诱导外周血淋巴细胞促进大鼠面神经再生的实验研究

目的:通过在神经缺损处局部回输体外分离培养纯化的淋巴细胞,了解此种方法促进面神经损伤修复的效果。方法:将20只Wistar大鼠的面神经颊支剪断并立即缝合(其余3支反折缝合)制成面神经损伤模型大鼠,将其分成淋巴细胞组和对照组,每组10只,每组再分成2周组和8周组。淋巴细胞组局部回输体外分离培养的外周血淋巴细胞,对照组作对照。于2周和8周测定面神经颊支-触须肌复合动作电位传导速度,辣根过氧化物酶(HRP)神经逆行示踪测定面神经核团的神经元阳性数目。结果:淋巴细胞组面神经颊支-触须肌复合动作电位传导速度8周时为0.64±0.07,与对照组(0.56±0.07)相比,差异有统计学意义(P<0.05)。HRP神经逆行示踪测定面神经核团神经元阳性数目,淋巴细胞组2周及8周与对照组同时间段相比差异均无统计学意义(均P>0.05)。结论:体外分离培养纯化的淋巴细胞在局部应用于神经损伤处对面神经再生修复可起一定的促进作用。     

深低温冷冻肌腱细胞活性的研究

目的研究深低温冷冻方法对肌腱细胞活性的影响,比较程序性降温和普通深低温冷冻法对腱细胞活性的影响.方法纯种SD大鼠24只（出生21 d）,随机分为3组,取双侧跟腱.新鲜肌腱对照组（A）,常规深低温冷冻组（B）,程序性降温深低温冷冻组（C）.采用相同的方法对3组肌腱细胞进行细胞培养.相差显微镜观察原代和传代后细胞的生长,绘制细胞的生长曲线,考察细胞的活性;对细胞进行成纤维细胞染色、胶原染色和对细胞进行形态观察（扫描电镜）;水解法定量分析细胞培养基中羟脯氨酸浓度的变化,检测细胞合成胶原的能力.结果原代细胞培养时A组细胞的生长速度快于B组和C组（P＜0.01）,C组细胞的生长速度快于B组（P＜0.01）,这种生长速度的差异在细胞传代后消失.细胞的形态学和组织学符合成纤维细胞形态.3组细胞培养基中羟脯氨酸浓度变化的差异无统计意义（P＞0.05）.结论经深低温冷冻处理的肌腱中仍存在具有活性的腱细胞,但数量显著少于新鲜肌腱中活细胞的数量.应用计算机控制程序性慢速降温方法处理的肌腱其活细胞的数量有所提高,但仍低于新鲜肌腱中活细胞的数量.     

细胞内游离Ca2+在发育中大鼠皮层神经元无镁诱导惊厥性损伤中的作用

目的: 观察细胞内游离Ca2+([Ca2+]i)在培养的不同发育阶段皮层神经元无镁诱导惊厥性损伤中的作用,探讨惊厥性脑损伤年龄依赖性的可能机制.方法:体外培养6 d、17 d的胚胎大鼠皮层神经元用无镁细胞外液处理3 h,或于无镁处理前用NMDA(N-甲基-D-门冬氨酸)受体拮抗剂或Ca2+通道阻滞剂预处理,用MTT代谢率测定的方法检测神经元损伤,以Fluo-3作标记用激光共聚焦显微镜扫描的方法检测[Ca2+]i.结果:体外培养6 d、17 d的神经元单纯无镁组MTT代谢率较同期对照组降低.应用MK-801 10 μmol*L-1、AP-5 50 μmol*L-1、尼莫地平10 μmol*L-1预处理后再给无镁处理,培养6 d、17 d的神经元MTT代谢率均不同程度高于同期单纯无镁组.培养6 d、17 d的神经元相对荧光强度之间差异有显著性,两者与基线荧光强度比较差异亦有显著性.应用上述各种拮抗剂后,[Ca2+]i改变的峰值均明显低于同期单纯无镁组.结论: 在体外不同发育阶段的神经元,短暂无镁处理诱导惊厥样放电所引起的神经元线粒体功能损伤以及[Ca2+]i改变程度不同.这种[Ca2+]i改变的年龄依赖性可能是惊厥导致神经元损伤的年龄依赖性的机制之一.NMDA受体-Ca2+通道激活是导致这种[Ca2+]i改变及神经元损伤的关键环节.     

Phenotypes and spontaneous cell cytotoxicity of mononuclear cells from patients with seronegative spondyloarthropathies: Ankylosing spondylitis,psoriatic arthropathy and pauciarticular juvenile chronic arthritis — Analysis of mononuclear cells from peripheral blood,synovial fluid and synovial membranes

Summary T-cell subpopulations and natural killer (NK) cells from peripheral blood, synovial fluid and synovial membranes from patients with seronegative spondyloarthropathies were investigated. Thirty-four patients with ankylosing spondylitis, sixteen patients with psoriatic arthropathy and six patients with pauciarticular juvenile chronic arthritis were studied. All the patient groups had normal proportions of T4⁺ and T8⁺ cells as well as normal T4/T8 ratios in peripheral blood. In the synovial fluids the T4/T8 ratios were reduced in ankylosing spondylitis and psoriatic arthropathy (p<0.05). Although both the T4 and T8 subpopulations were reduced, the T4/T8 ratios in the synovial membranes of patients with these two disorders tended to be within the normal range of that of peripheral blood. Increased numbers of T-cells in the synovial fluid from patients with ankylosing spondylitis expressed class II MHC antigens. The natural killer cell activity was normal in peripheral blood and synovial fluids of patients with ankylosing spondylitis and psoriatic arthropathy while it tended to be reduced, although not significantly, in pauciarticular juvenile chronic arthritis. Synovial membranes were almost devoid of NK cell activity. The number of Leu 7⁺ cells were reduced in synovial fluid of patients with psoriatic arthropathy (p<0.04), but not as significantly as in the two other patient groups.     

力达霉素对神经胶质瘤细胞血管生成拟态的抑制及对细胞凋亡的影响

Objective To evaluate the in vitro effects of lidamycin upon vasculogenic mimicry and apoptosis induction in glioma cells. Methods Tube formation assay was performed to estimate the inhibitory effects of lidamycin upon vasculogenic mimicry in C6 and U87 glioma cells. The vasculogenic mimicry of glioma cells was photographed and enumerated. Annexin V-FITC/PI was used for determination of glioma cell apoptosis with flow cytometry. Results Vasculogenic mimicry assay indicated that 0. 1 nmol/L, 0. 5 nmol/L and 1 nmol/L lidamycin showed significant inhibition of vasculogenic mimicry in C6 and U87 cells. Comparing with C6 control group (14. 7 ± 1.2), 0. 1 nmol/L (12. 7 ± 0. 6), 0. 5 nmol/L (9. 0 ± 1.7) and 1 nmol/L (4. 7 ± 0. 6) lidamycin inhibited vasculogenic mimicry in C6 cells with statistical significances (P = 0. 013, P = 0. 005 and P = 0. 0002 respectively). Comparing with U87 control group (14.7±1.2), the vasculogenic mimicry of 0.1 nmol/L (10.0±2.0), 0.5 nmol/L (8.3±1.5) and 1 nmol/L lidamycin (4. 3±0. 6) treated U87 cells showed statistical significances (P =0. 025, P =0. 005 and P =0. 0009 respectively). The apoptotic ratios of same dosages lidamycin treated C6 cells and U87 cells showed a similar tendency as vaaculogenic mimicry inhibition (P < 0. 001). Lidamycin was more potent than neocarzinostatin in vasculogenic mimicry inhibition and apoptosis induction of C6 cells and U87 cells. Conclusion Lidamycin can inhibit vasculogenic mimicry and promote apotosis of glioma cells. Thus it is a promising drug in glioma treatment. Further researches on the therapeutic efficacy of enediyne antibiotics in glioma are needed.     

大肠癌Lovo细胞E-Cadherin,N-Cadherin的表达及化学治疗药物对其表达的影响

目的：研究大肠癌Lovo细胞上皮钙粘附素(E-Cadherin)，神经钙粘附素(N-Cadherin)的表达及常用化学治疗药物对其表达的影响。方法：应用逆转录聚合酶链反应(RT-PCR)法检测大肠癌Lovo细胞E-Cad-herin，N-Cadherin的表达，并通过几种不同的化疗药物(顺铂、吡柔比星、丝裂霉素、5-FU)不同浓度和时间作用后，对E-Cadherin，N-Cadherin表达的影响。结果：不同化疗药物对大肠癌Lovo细胞N=Cadherin表达无影响，高浓度顺铂和高浓度吡柔比星二组出现-Cadherin表达，其它各组未见表达。结论：大肠癌常用的化疗药物无论低浓度持续用药，还是高浓度短时间用药，对大肠癌Lovo细胞N-Cadherin的表达无抑制作用，说明上述药物不能通过抑制N—Cadherin的表达，而起到抗癌作用。高浓度顺铂和吡柔比星二组显示E-Cadherin的表达，表现出抑癌的作用，从而提示在大肠癌化疗时，顺铂和吡柔比星更适合于高浓度短时间应用。     

二氧化硅活化巨噬细胞中早期生长反应因子-1及其信号转导通路的研究

目的 探讨早期生长反应因子(Egr-1)及其信号转导在矽肺发生发展中的作用。方法用细胞免疫荧光、原位杂交方法检测二氧化硅(SiO2)刺激后Egr-1的表达定位,用报道质粒及EMSA检测其活性改变;用激酶活性分析法检测si0：刺激巨噬细胞后ERK1／2活性改变,进一步用激酶抑制剂初步探讨SiO2活化Egr-1的信号转导通路。结果SiO2刺激RAW264．7细胞短时间Egr-1核蛋白表达及转录因子明显增加;且在处理后30～60min,Egr-1核蛋白结合活性明显升高(为未处理组的20倍);在刺激后15min ERK1／2活性开始升高,30min达高峰(活性为对照组的29倍)而后渐降至基础水平;进一步用激酶阻断发现,Egr-1 mRNA及蛋白表达均减少。结论SiO2能激活巨噬细胞中Egr-1,且此过程可能由ERK1／2、p38介导,提示SiO2-ERK1／2、p38-Egr-1通路可能在矽肺发生发展过程中起重要作用。     

人白细胞介素12在哺乳动物细胞中的稳定表达及其生物活性的研究

目的采用遗传基因工程方法获得具有生物活性的人白细胞介素12,探索其治疗肿瘤和慢性肝炎的可行性。方法采用已克隆的国人IL-12基因序列,利用内部核糖体切入位点(IRES)完成IL-12P35、P40双亚基共表达载体的构建,通过转染CHODHFR缺陷细胞,双抗夹心ELISA法筛选阳性克隆,MTX加压扩增,PCR检测其基因整合,T淋巴细胞增殖和诱生γ干扰素实验检测其生物活性。结果获得了稳定高效表达人IL-12的工程细胞系,表达产物为70×103左右的糖蛋白。结论本研究得到的基因重组人IL-12具有良好的生物活性,有强的诱导产生γ干扰素的能力和诱导活化T淋巴细胞增殖能力。